Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
Zucara Therapeutics has raised $5.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
Zucara Therapeutics's investors include Sanofi, Perceptive Advisors, Breakthrough T1D, Mitacs, Canadian Glycomics Network.
Zucara Therapeutics is headquartered in Vancouver, Canada.
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
Zucara Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Zucara Therapeutics — Funding & Investors." VCBacked, May 1, 2025, https://www.vcbacked.co/company/zucara-therapeutics. Accessed September 16, 2026.
VCBacked. (2025). Zucara Therapeutics — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/zucara-therapeutics
{{cite web |title=Zucara Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/zucara-therapeutics |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated